Anne Nagengast Johnson net worth and biography

Anne Johnson Biography and Net Worth

CFO of Atai Beckley

Anne became Chief Financial Officer in 2024, previously serving as Chief Accounting Officer and Vice President of Finance and Global Controller since joining atai in 2022. She oversees finance, accounting, financial planning & analysis, tax and treasury and investor relations.

With more than three decades in corporate finance, Anne has held multiple leadership positions, drove four IPOs and other major financing transactions. She has spent most of her career in the life sciences sector and has a deep personal connection to mental health.

Anne is a Certified Public Accountant (CPA) and a Chartered Management Accountant (CGMA) and holds a B.Sc in Accounting from the University of North Carolina at Wilmington.

What is Anne Nagengast Johnson's net worth?: The estimated net worth of Anne Nagengast Johnson is at least $612.00 thousand as of March 21st, 2025. Johnson owns 140,045 shares of Atai Beckley stock worth more than $611,997 as of February 24th. This net worth approximation does not reflect any other assets that Johnson may own. Additionally, Johnson receives a salary of $494,230.00 as CFO at Atai Beckley. Learn More about Anne Nagengast Johnson's net worth.
How old is Anne Nagengast Johnson?: Johnson is currently 55 years old. There are 5 older executives and no younger executives at Atai Beckley. Learn More on Anne Nagengast Johnson's age.
What is Anne Nagengast Johnson's salary?: As the CFO of Atai Beckley N.V., Johnson earns $494,230.00 per year. There are 2 executives that earn more than Johnson. The highest earning executive at Atai Beckley is Dr. Srinivas G. Rao M.D., Ph.D., Co-Founder & Co-CEO, who commands a salary of $793,650.00 per year. Learn More on Anne Nagengast Johnson's salary.
How do I contact Anne Nagengast Johnson?: The corporate mailing address for Johnson and other Atai Beckley executives is c/o Mindspace Krausenstra sse 9-10, Berlin, Berlin 10117. Atai Beckley can also be reached via phone at 31 20 793 2536 and via email at [email protected]. Learn More on Anne Nagengast Johnson's contact information.
Has Anne Nagengast Johnson been buying or selling shares of Atai Beckley?: Anne Nagengast Johnson has not been actively trading shares of Atai Beckley in the last ninety days. Most recently, Anne Nagengast Johnson sold 33,545 shares of the business's stock in a transaction on Friday, March 21st. The shares were sold at an average price of $1.35, for a transaction totalling $45,285.75. Following the completion of the sale, the chief financial officer now directly owns 140,045 shares of the company's stock, valued at $189,060.75. Learn More on Anne Nagengast Johnson's trading history.
Who are Atai Beckley's active insiders?: Atai Beckley's insider roster includes Christian Angermayer (Director), Anne Johnson (CFO), Sahil Kirpekar (Insider), Srinivas Rao (Insider), and Gregory Weaver (CFO). Learn More on Atai Beckley's active insiders.
Are insiders buying or selling shares of Atai Beckley?: During the last year, insiders at the sold shares 2 times. They sold a total of 82,108 shares worth more than $110,845.80. The most recent insider tranaction occured on March, 21st when insider Sahil Kirpekar sold 48,563 shares worth more than $65,560.05. Insiders at Atai Beckley own 26.8% of the company. Learn More about insider trades at Atai Beckley.
Information on this page was last updated on 3/21/2025.

Anne Nagengast Johnson Insider Trading History at Atai Beckley

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
3/21/2025	Sell	33,545	$1.35	$45,285.75	140,045
4/2/2024	Sell	27,410	$1.85	$50,708.50	73,590

Anne Nagengast Johnson Buying and Selling Activity at Atai Beckley

Atai Beckley Company Overview

Atai Beckley N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. Atai Beckley N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.

Today's Range

Now: $4.37

$3.94

$4.37

50 Day Range

MA: $3.89

$3.41

$4.33

2 Week Range

Now: $4.37

$1.15

$6.75

Volume

6,943,864 shs

Average Volume

4,000,717 shs

Market Capitalization

$1.59 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.61

Anne Johnson Biography and Net Worth

What is Anne Nagengast Johnson's net worth?

How old is Anne Nagengast Johnson?

What is Anne Nagengast Johnson's salary?

How do I contact Anne Nagengast Johnson?

Has Anne Nagengast Johnson been buying or selling shares of Atai Beckley?

Who are Atai Beckley's active insiders?

Are insiders buying or selling shares of Atai Beckley?